Related references
Note: Only part of the references are listed.A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy
A Gschwind et al.
NATURE REVIEWS CANCER (2004)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Oncogenic transformation induced by membrane-targeted Akt2 and Akt3
I Mende et al.
ONCOGENE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
